Program: Oral and Poster Abstracts
Monday, December 12, 2011: 7:00 AM-8:30 AM
Room 30 (San Diego Convention Center)
Peter G. Maslak, M.D., Memorial Sloan-Kettering Cancer Center and Rebecca L. Olin, MD, MS, UCSF
No relevant conflicts of interest to declare.
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC
See more of: Oral and Poster Abstracts
*signifies non-member of ASH